PT2477648T - Terapia sinérgica anti-cd47 para cancros hematológicos - Google Patents

Terapia sinérgica anti-cd47 para cancros hematológicos

Info

Publication number
PT2477648T
PT2477648T PT108177932T PT10817793T PT2477648T PT 2477648 T PT2477648 T PT 2477648T PT 108177932 T PT108177932 T PT 108177932T PT 10817793 T PT10817793 T PT 10817793T PT 2477648 T PT2477648 T PT 2477648T
Authority
PT
Portugal
Prior art keywords
therapy
synergistic anti
hematologic cancers
hematologic
cancers
Prior art date
Application number
PT108177932T
Other languages
English (en)
Original Assignee
The Board Of Trustees Of The Univ Of The Leland Stanford Junior Univ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43758999&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2477648(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Board Of Trustees Of The Univ Of The Leland Stanford Junior Univ filed Critical The Board Of Trustees Of The Univ Of The Leland Stanford Junior Univ
Publication of PT2477648T publication Critical patent/PT2477648T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
PT108177932T 2009-09-15 2010-09-15 Terapia sinérgica anti-cd47 para cancros hematológicos PT2477648T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27672609P 2009-09-15 2009-09-15

Publications (1)

Publication Number Publication Date
PT2477648T true PT2477648T (pt) 2022-10-27

Family

ID=43758999

Family Applications (1)

Application Number Title Priority Date Filing Date
PT108177932T PT2477648T (pt) 2009-09-15 2010-09-15 Terapia sinérgica anti-cd47 para cancros hematológicos

Country Status (9)

Country Link
US (4) US8758750B2 (pt)
EP (2) EP2477648B1 (pt)
AU (1) AU2010295661B2 (pt)
CA (2) CA3057650A1 (pt)
ES (1) ES2927646T3 (pt)
PL (1) PL2477648T3 (pt)
PT (1) PT2477648T (pt)
SI (1) SI2477648T1 (pt)
WO (1) WO2011034969A1 (pt)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2242512T3 (en) 2008-01-15 2016-06-06 Univ Leland Stanford Junior Method for manipulating phagocytosis mediated by CD47
US11072655B2 (en) 2008-01-15 2021-07-27 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
CA3221018A1 (en) 2008-01-15 2009-07-23 Ravindra Majeti Markers of acute myeloid leukemia stem cells
EP2111869A1 (en) * 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
US9873918B2 (en) 2011-08-11 2018-01-23 Albert Einstein College Of Medicine, Inc. Treatment of acute myeloid leukemia and myelodysplastic syndromes
EP2812443B1 (en) 2012-02-06 2019-05-29 Inhibrx, Inc. Cd47 antibodies and methods of use thereof
PT2850106T (pt) * 2012-05-18 2022-07-18 Aptevo Res & Development Llc Imunofusão biespecífica (bif) de scfv de ligação a cd123 e cd3
CN105121467B (zh) * 2012-12-03 2019-07-05 诺夫免疫股份有限公司 抗cd47抗体及其使用方法
US9221908B2 (en) 2012-12-12 2015-12-29 Vasculox, Inc. Therapeutic CD47 antibodies
BR112015013431A2 (pt) 2012-12-12 2017-11-14 Vasculox Inc anticorpos monoclonais ou respectivos fragmentos ligantes de antígenos, composição farmacêutica, e usos de anticorpo monoclonal ou respectivo fragmento ligante de antígenos
US9873747B2 (en) 2013-01-31 2018-01-23 Thomas Jefferson University Fusion proteins that facilitate cancer cell destruction
WO2014160183A1 (en) * 2013-03-13 2014-10-02 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Methods for modulating chemotherapeutic cytotoxicity
US9623079B2 (en) * 2013-03-15 2017-04-18 The Board Of Trustees Of The Leland Stanford Junior University Methods for achieving therapeutically effective doses of anti-CD47 agents for treating cancer
WO2014186761A2 (en) * 2013-05-17 2014-11-20 The Board Of Trustes Of The Leland Stanford Junior University Methods for determining responsiveness to an anti-cd47 agent
NL2011904C2 (en) * 2013-12-06 2015-06-09 Stichting Vu Vumc Leukemic stem cell markers.
EP3553087A1 (en) * 2014-01-08 2019-10-16 The Board of Trustees of the Leland Stanford Junior University Targeted therapy for lung cancer
AU2015229448B2 (en) 2014-03-11 2020-09-03 The Board Of Trustees Of The Leland Stanford Junior University Anti SIRP-alpha antibodies and Bi-specific Macrophage Enhancing antibodies
CA2957531A1 (en) * 2014-08-08 2016-02-11 The Board Of Trustees Of The Leland Stanford Junior University Sirp alpha-antibody fusion proteins
EP3180363B2 (en) 2014-08-15 2022-09-14 Merck Patent GmbH Sirp-alpha immunoglobulin fusion proteins
SI3656869T1 (sl) 2014-08-26 2021-03-31 The Board Of Trustees Of The Leland Stanford Junior University Vsaditev matičnih celic s kombinacijo sredstva, ki cilja matične celice in modulacija imunoregulatornega signaliziranja
EP3204420B1 (en) * 2014-10-10 2020-09-02 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods to eliminate cancer stem cells by targeting cd47
SI3850946T1 (sl) * 2014-12-05 2024-02-29 Regeneron Pharmaceuticals, Inc. Nehumane živali, ki imajo humaniziran grozd diferenciacije gena 47
SG11201705310TA (en) 2014-12-30 2017-07-28 Celgene Corp Anti-cd47 antibodies and uses thereof
AU2016232719A1 (en) * 2015-03-18 2017-10-12 Memorial Sloan Kettering Cancer Center Compositions and methods for targeting CD99 in haematopoietic and lymphoid malignancies
JP7198083B2 (ja) 2015-08-26 2022-12-28 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Ｃｄ４７遮断及び免疫同時刺激アゴニストを用いた標的細胞の枯渇亢進
UA126146C2 (uk) 2015-09-18 2022-08-25 Арч Онколоджі, Інк. Терапевтичне антитіло до cd47
EP3353209B1 (en) 2015-09-21 2022-03-16 Erasmus University Medical Center Rotterdam Anti-cd47 antibodies and methods of use
US20170189548A1 (en) * 2015-11-25 2017-07-06 Immunogen, Inc. Pharmaceutical formulations and methods of use thereof
CN109152824B (zh) 2015-11-27 2022-12-06 卡瑟里克斯私人有限公司 经遗传修饰的细胞及其用途
US10946042B2 (en) * 2015-12-01 2021-03-16 The Trustees Of The University Of Pennsylvania Compositions and methods for selective phagocytosis of human cancer cells
CA3177526A1 (en) 2016-01-11 2017-07-20 Forty Seven, Inc. Humanized, mouse or chimeric anti-cd47 monoclonal antibodies
US20170210803A1 (en) * 2016-01-21 2017-07-27 The Board Of Trustees Of The Leland Stanford Junior University Treatment of cancer with combinations of immunoregulatory agents
CA3020026A1 (en) * 2016-04-15 2017-10-19 Trillium Therapeutics Inc. Macrophage stimulation in cd47 blockade therapy
JP7160683B2 (ja) 2016-04-29 2022-10-25 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 術後癒着の予防及び治療のための方法及び組成物
WO2017205721A1 (en) 2016-05-27 2017-11-30 Agenus Inc. Anti-tim-3 antibodies and methods of use thereof
JP7241677B2 (ja) 2016-07-19 2023-03-17 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 抗ｃｄ４７併用療法
EP3494228B1 (en) * 2016-08-03 2021-07-07 CBmed GmbH Center for Biomarker Research in Medicine Method for prognosing and diagnosing tumors
EP3493845A4 (en) 2016-08-03 2020-04-15 The Board of Trustees of the Leland Stanford Junior University INTERRUPTION OF FC RECEPTOR USE ON MACROPHAGES TO IMPROVE THE EFFECTIVENESS OF ANTI-SIRPALPHA ANTIBODY THERAPY
AU2017331256A1 (en) 2016-09-21 2019-04-04 Aptevo Research And Development Llc CD123 binding proteins and related compositions and methods
WO2018075960A1 (en) 2016-10-21 2018-04-26 Tioma Therapeutics, Inc. Therapeutic cd47 antibodies
EP3532497A4 (en) 2016-10-26 2020-05-13 The Board of Trustees of the Leland Stanford Junior University MODIFIED IMMUNOGLOBULIN BAND REGIONS TO REDUCE HEMAGGLUTINATION
EP3345924A1 (en) 2017-01-10 2018-07-11 Universität Duisburg-Essen Use of cd47 antibodies
US11078272B2 (en) 2017-03-09 2021-08-03 The Board Of Trustees Of The Leland Stanford Junior University Treatment of pediatric brain tumors with targeting of CD47 pathway
WO2018237168A1 (en) * 2017-06-21 2018-12-27 The Board Of Trustees Of The Leland Stanford Junior University DOSING PARAMETERS FOR CD47 TARGETING THERAPIES WITH HEMATOLOGICAL MALIGNANCIES
KR102646468B1 (ko) 2017-08-02 2024-03-11 페인스 테라퓨틱스 인코포레이티드 항-cd47 항체 및 이의 용도
CN109422811A (zh) 2017-08-29 2019-03-05 信达生物制药(苏州)有限公司 抗cd47抗体及其用途
EP4177270A1 (en) 2017-10-18 2023-05-10 Forty Seven, Inc. Anti-cd47 agent-based ovarian cancer therapy
WO2019086573A1 (en) 2017-11-01 2019-05-09 Hummingbird Bioscience Holdings Pte. Ltd. Cd47 antigen-binding molecules
WO2019086574A1 (en) * 2017-11-01 2019-05-09 Hummingbird Bioscience Holdings Pte. Ltd. Cd47 and cd33 antigen-binding molecules
PT3752190T (pt) 2018-02-12 2022-11-18 Forty Seven Inc Regime anticancerígeno usando anticorpos anti-cd47 e anti-cd20
CN110305212A (zh) 2018-03-27 2019-10-08 信达生物制药(苏州)有限公司 抗cd47抗体及其用途
CN112639079A (zh) * 2018-07-17 2021-04-09 加利福尼亚大学董事会 从免疫工程化多能细胞分化的细胞
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
EA202190986A1 (ru) 2018-11-26 2021-12-14 Фоти Севен, Инк. ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К c-Kit
AR117327A1 (es) 2018-12-20 2021-07-28 23Andme Inc Anticuerpos anti-cd96 y métodos de uso de estos
US11162079B2 (en) 2019-05-10 2021-11-02 The Regents Of The University Of California Blood type O Rh-hypo-immunogenic pluripotent cells
CN114599392A (zh) * 2019-10-31 2022-06-07 四十七公司 基于抗cd47和抗cd20的血癌治疗
CN110755635B (zh) * 2019-11-14 2022-10-11 天津大学 Flu@α-cd47@RGD制剂的合成方法
US20210221886A1 (en) * 2019-12-05 2021-07-22 Sorrento Therapeutics, Inc. Compositions and Methods Comprising an Anti-CD47 Antibody in Combination with a Tumor Targeting Antibody
WO2022130016A1 (en) 2020-12-18 2022-06-23 Instil Bio (Uk) Limited Tumor infiltrating lymphocytes and anti-cd47 therapeutics
US20230071148A1 (en) * 2021-07-15 2023-03-09 Vcreate, Inc. Compositions and Methods for Making Novel T-Cell Receptors
WO2023165618A1 (en) * 2022-03-04 2023-09-07 Nanjing University Methods for treating cancer

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4489710A (en) 1981-06-23 1984-12-25 Xoma Corporation Composition and method for transplantation therapy
US4429008B1 (en) 1981-12-10 1995-05-16 Univ California Thiol reactive liposomes
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US5156840A (en) 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
JPS59116229A (ja) 1982-12-24 1984-07-05 Teijin Ltd 細胞毒性複合体を活性成分とする癌治療用剤およびその製造法
US4873088A (en) 1983-09-06 1989-10-10 Liposome Technology, Inc. Liposome drug delivery method and composition
US4625014A (en) 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4638045A (en) 1985-02-19 1987-01-20 Massachusetts Institute Of Technology Non-peptide polyamino acid bioerodible polymers
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5945098A (en) 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
AU6445894A (en) 1993-03-19 1994-10-11 Duke University Method of treatment of tumors with an antibody binding to tenascin
US5747654A (en) 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
UA40577C2 (uk) 1993-08-02 2001-08-15 Мерк Патент Гмбх Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин
US5985660A (en) 1994-06-15 1999-11-16 Systemix, Inc. Method of identifying biological response modifiers involved in dendritic and/or lymphoid progenitor cell proliferation and/or differentiation
IL114909A (en) 1994-08-12 1999-10-28 Immunomedics Inc Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
CN1173878A (zh) 1995-10-16 1998-02-18 尤尼利弗公司 双功能或双价抗体片段类似物
FR2741892B1 (fr) 1995-12-04 1998-02-13 Pasteur Merieux Serums Vacc Procede de preparation d'une banque multicombinatoire de vecteurs d'expression de genes d'anticorps, banque et systemes d'expression d'anticorps "coliclonaux" obtenus
CA2226962A1 (en) * 1998-02-16 1999-08-16 Marie Sarfati Use of binding agents to cd47 and its ligands in the treatment or the prophylaxis of various inflammatory, autoimmune and allergic diseases and in the treatment of graft rejection
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
JP2005526044A (ja) * 2002-02-21 2005-09-02 デューク ユニバーシティ 抗ｃｄ２２抗体を使用した治療方法
AU2003294210A1 (en) * 2002-07-31 2004-05-04 Seattle Genetics, Inc Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
CA2545166A1 (en) 2003-11-11 2005-05-19 Chugai Seiyaku Kabushiki Kaisha Humanized anti-cd47 antibody
WO2007053189A2 (en) 2005-06-01 2007-05-10 Northwestern University Compositions and methods for altering immune function
US20090191202A1 (en) 2005-09-29 2009-07-30 Jamieson Catriona Helen M Methods for manipulating phagocytosis mediated by CD47
EP2139922A1 (en) 2007-03-28 2010-01-06 Biogen Idec, Inc. Treatment of hodgkins lymphoma
CA3221018A1 (en) 2008-01-15 2009-07-23 Ravindra Majeti Markers of acute myeloid leukemia stem cells
DK2242512T3 (en) 2008-01-15 2016-06-06 Univ Leland Stanford Junior Method for manipulating phagocytosis mediated by CD47
EP2111869A1 (en) * 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system

Also Published As

Publication number Publication date
PL2477648T3 (pl) 2022-11-07
US20190048075A1 (en) 2019-02-14
US20120282174A1 (en) 2012-11-08
SI2477648T1 (sl) 2022-09-30
EP4134095A1 (en) 2023-02-15
US20210214437A1 (en) 2021-07-15
US8758750B2 (en) 2014-06-24
ES2927646T3 (es) 2022-11-08
EP2477648A1 (en) 2012-07-25
CA3057650A1 (en) 2011-03-24
AU2010295661B2 (en) 2015-04-30
AU2010295661A1 (en) 2012-03-22
US20140369924A1 (en) 2014-12-18
CA2771336A1 (en) 2011-03-24
EP2477648B1 (en) 2022-07-20
CA2771336C (en) 2019-11-26
EP2477648A4 (en) 2013-05-08
WO2011034969A1 (en) 2011-03-24

Similar Documents

Publication Publication Date Title
EP2477648A4 (en) SYNERGISTIC ANTI-CD47 THERAPY FOR HEMATOLOGICAL CANCER
HUS1800001I1 (hu) Kombinációs terápia COPD-hez
HK1200363A1 (en) Compounds useful for treating cancer
HK1175476A1 (en) Cancer treatment
IL206654A0 (en) Combination therapy
PL2440287T3 (pl) Urządzenie do terapii fotodynamicznej
EP2506875A4 (en) METHOD FOR THE TREATMENT OF TUMORS WITH K-RAS MUTATIONS
EP2621497A4 (en) ASSOCIATION TREATMENT FOR ROSE ACNE
PL2957292T3 (pl) Terapia w przypadku bielactwa nabytego
GB201013898D0 (en) Well treatment
GB0901465D0 (en) Compounds for use in therapy
ZA201201894B (en) Pharmaceutical combination for treating tumor
GB0916997D0 (en) Combination therapy
GB0803948D0 (en) Combination therapy
GB0707556D0 (en) Treatment for cancer
GB0809046D0 (en) Cancer treatment
GB0907973D0 (en) Combination therapy
GB0921102D0 (en) Cancer Therapy
GB0913603D0 (en) Cancer therapy
GB0901497D0 (en) Compound for therapy
GB0903080D0 (en) Compound for therapy
GB0914441D0 (en) Compound for therapy
GB0921244D0 (en) Therapy
GB0914820D0 (en) WATerian therapy
GB0903321D0 (en) Therapy